NOUL Co., Ltd. AI-powered malaria diagnostic solution miLab™ MAL has been officially adopted by Benin's National Malaria Control Program following a public procurement tender by the Ministry of Health.
Public source
Publisher name
Public post
🦟We are proud to see miLab™ MAL taking another step forward in strengthening malaria diagnostics in Africa. Noul’s AI-powered malaria diagnostic solution has been offic…
Company
NOUL Co., Ltd.
- Industry
- Biotechnology Research
- Location
- Yongin-si, KR
- Company size
- 51–200 employees
About NOUL Co., Ltd.
Noul Inc. has developed the next generation POC (Point-Of-Care) blood testing platform for resource-limited medical facilities, clinics, and local hospitals. Noul seeks to solve global challenges that threaten human life, to discover novel solutions, and to establish a new gold standard in POC blood testing. Noul’s solution aims to improve accessibility to proper health care by integrating innovations in biology, artificial intelligence, mobile technology, robotics, and software/hardware engineering. Noul has filed over 65 global patents, conducted more than seven field clinical trials, and has research partnerships with world-class global institutions. [Mission] We explore global challenges that threaten human health and life, discover novel potential solutions, and realize those possibilities. [Goal] 1. To contribute to eliminating malaria, tb, aids and other neglected diseases through innovative diagnostic platform. 2. To proactively increase healthcare accessibility through next-generation blood diagnostics platform.
See moreLatest activity
Latest activity from NOUL Co., Ltd.
3 signals
Presence & Recognition
NOUL Co., Ltd. will present an e-poster on miLab™ BCM at the ECP2026 European Congress of Pathology in Stockholm, Sweden from September 12 to 16, 2026.
Presence & Recognition
NOUL Co., Ltd. will be attending the 8th Korea-Africa Economic Cooperation Ministerial Conference at Grand Walkerhill Seoul, Seoul, Korea from September 8 to 11, 2026, under the theme “Harnessing AI and Digital Infrastructure for Africa’s Transformation,” showcasing the miLab™ and featuring David Lim as a speaker at the Ministerial Roundtable.
Discover more
Similar signals
Similar public activity from other companies.
Customers & Market
BioSystems
BioSystems has supported Blanco Salud for over three years in the implementation and optimisation of BioSystems A15 technology for Calprotectin and the incorporation of specialised techniques for complex clinical diagnostics.
Customers & Market
MedPal AI plc
MedPal AI plc recorded more than 16,000 new customers in a matter of weeks for New Health.
Customers & Market
Patholytix
Patholytix welcomed Scantox Group as a customer to expand its digital pathology capability and provide GLP studies with digitally scanned slides.
Customers & Market
Clever Culture Systems
Clever Culture Systems announced that Novo Nordisk has ordered two additional APAS Independence instruments bringing its installed base to three.
Customers & Market
N-Power Medicine, Inc.